

## Results of AGM and Issue of New Securities

Aurora Labs Limited (Aurora Labs or the "Company") is pleased to provide the results of its Annual General Meeting (AGM) held this morning.

In accordance with ASX listing rule 3.13.2 and Section 251 AA of the Corporations Act 2001, the details of the resolutions and the proxies received in respect of each resolution are as follows:

### 1. Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
9,250,997	30,350	14,227	695,000

The resolution was passed on a show of hands as an ordinary resolution.

### 2. Re-election of Director - Mr Nathan Henry

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
34,903,933	350	14,227	1000

The resolution was passed on a show of hands as an ordinary resolution.

### 3. Re-election of Director - Mr Mathew Whyte

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
34,903,933	350	14,227	1,000

The resolution was passed on a show of hands as an ordinary resolution.

### 4. Appointment of Auditor

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
34,904,283	Nil	14,227	1,000

The resolution was passed on a show of hands as an ordinary resolution.

### 5. Grant of Tranche 1 Options to David Budge

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
6,434,109	3,542,238	14,227	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 6. Grant of Tranche 1 Options to Nathan Henry

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
6,434,109	3,542,238	14,227	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 7. Grant of Tranche 1 Options to Mathew Whyte

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
6,434,109	3,542,238	14,222	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 8. Grant of Tranche 2 options to Mathew Whyte

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
6,434,109	3,542,238	14,222	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 9. Approval of Redemption and Cancellation of Class A Performance Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
8,718,196	5,000	14,222	Nil

The resolution was passed on a show of hands as a special resolution.

## 10. Approval of Termination Benefits for David Budge

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
10,922,148	36,500	14,222	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 11. Approval of Termination Benefits for Nathan Henry

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
33,886,782	36,500	14,222	Nil

The resolution was passed on a show of hands as an ordinary resolution.

## 12. Approval of Additional Placement Facility

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Proxy's Discretion	Abstain
34,204,283	6,000	14,222	Nil

The resolution was passed on a show of hands as a special resolution.

### **Issue of new securities**

The Company also provides the following in relation to the issue of unquoted securities as approved by Shareholders pursuant to Resolution 5,6,7 and 8 above:

1. Appendix 3B – New Issue Announcement;
2. Appendix 3Y – Change of Directors Interest Notice for Mr David Budge;
3. Appendix 3Y – Change of Directors Interest Notice for Mr John Nathan Henry; and
4. Appendix 3Y – Change of Directors Interest Notice for Mr Mathew Whyte.

For further information please contact:

[enquiries@auroralabs3d.com](mailto:enquiries@auroralabs3d.com)

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Aurora Labs Limited

ABN

44 601 164 505

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |   |  |  |
|---|--|--|
| 1 | +Class of +securities issued or to be issued   | Unquoted Options   |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | 145,000 Unquoted Options   |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Each Unquoted Option is granted pursuant to the Company's Employee Incentive Plan as follows: <ul style="list-style-type: none"><li>• 45,000 Tranche 1 Options exercisable at \$0.79 on or before 31 August 2020*; and</li><li>• 100,000 Tranche 2 Options exercisable at \$0.95 on or before 31 July 2020*.</li></ul> *Refer attached for full Terms and Conditions |

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

4	<p>Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>No.</p> <p>The shares issued on the exercise of Unquoted Options will rank equally with existing fully paid ordinary shares on issue at that time.</p>
5	<p>Issue price or consideration</p>	<p>The Unquoted Options were issued for nil cash consideration.</p>
6	<p>Purpose of the issue          (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>The Unquoted Options were granted to Directors Mr David Budge, Mr Nathan Henry and Mr Mathew Whyte pursuant to the Company's Employee Incentive Plan and pursuant to shareholder approval on 29 November 2017.</p>
6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
6b	<p>The date the security holder resolution under rule 7.1A was passed</p>	<p>29 November 2017</p>
6c	<p>Number of +securities issued without security holder approval under rule 7.1</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

For personal use only

6d	Number of +securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	145,000 Unquoted Options	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR 7.1 : 8,768,000 LR 7.1A: 5,845,758	
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	29 November 2017	
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	Number	+Class
		26,196,879	Ordinary Shares

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

	Number	+Class	
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	32,260,696	Ordinary Shares (restricted securities)
		1,499,925	Unquoted Options Exercisable at \$0.20 Expiring 31/12/2018 (A3DAH)
		9,092,500	Restricted Unquoted Options Exercisable at \$0.20 Expiring 31/12/2018 (A3DAG)
		480,000	Unquoted Options Exercisable at \$2.23 Expiring 30/11/2019 (A3DAI)
		931,000	Unquoted Options Exercisable at \$3.00 Expiring 31/03/2020 (A3DAI)
		40,000	Unquoted Options Exercisable at \$1.17 Expiring 30/06/2020 (A3DAI)
		477,000	Unquoted Options Exercisable at \$0.079 Expiring 31/08/2020 (A3DAI) (Includes 45,000 Options issued today)
		50,000	Unquoted Options Exercisable at \$0.072 Expiring 30/09/2020 (A3DAI)
		100,000	Unquoted Options Exercisable at \$0.095 Expiring 30/07/2020 (A3DAI) (Includes 100,000 Options issued today)
	14,700,000	Performance Shares (A3DAJ): <ul style="list-style-type: none"> <li>• 7,087,500 Class B</li> <li>• 7,612,500 Class C</li> </ul>	
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

+ See chapter 19 for defined terms.

For personal use only

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	+Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has +security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	

+ See chapter 19 for defined terms.

For personal use only



**Appendix 3B**  
**New issue announcement**

---

- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of <sup>+</sup>security holders
- 25 If the issue is contingent on <sup>+</sup>security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do <sup>+</sup>security holders sell their entitlements *in full* through a broker?
- 31 How do <sup>+</sup>security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?
- 33 <sup>+</sup>Despatch date

**Part 3 - Quotation of securities**

---

+ See chapter 19 for defined terms.

For personal use only

You need only complete this section if you are applying for quotation of securities

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

**Entities that have ticked box 34(a)**  
**Additional securities forming a new class of securities**

Tick to indicate you are providing the information or documents

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3B**  
**New issue announcement**

---

**Entities that have ticked box 34(b)**

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)	<input type="text"/>	<input type="text"/>

---

+ See chapter 19 for defined terms.

For personal use only

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



(Company Secretary)

Date: 29/11/ 2017

Print name: Mathew Whyte

== == == == ==

---

+ See chapter 19 for defined terms.

For personal use only

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	55,000,000
<p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p>100,000 (Shares issued 24/2/2017); 194,000 (Shares issued 29/8/2017); 167,500 (Shares issued 3/10/2017); 196,075 (Shares issued 13/11/2017);</p> <p>Issued on exercise of Options issued pursuant to Employee Option Plan. LR 7.2 exception 4).</p> <p>2,800,000 (Shares issued under Placement on 24/2/2017 ratified pursuant to LR 7.4 at EGM held on 12/6/2017)</p>
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil
<b>“A”</b>	58,457,575

+ See chapter 19 for defined terms.

For personal use only

For personal use only

<b>Step 2: Calculate 15% of "A"</b>	
<b>"B"</b>	<i>[Note: this value cannot be changed]</i>
<b>Multiply "A" by 0.15</b>	8,768,636
<b>Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	Nil
<b>"C"</b>	Nil
<b>Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1</b>	
<p>"A" x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	8,768,636
<p><b>Subtract "C"</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	Nil
<b>Total ["A" x 0.15] – "C"</b>	<p><b>8,768,636</b></p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

+ See chapter 19 for defined terms.

Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b>  <i>Note: number must be same as shown in Step 1 of Part 1</i>	58,457,575
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	<i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	5,845,758
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12- month period under rule 7.1A  <b>Notes:</b> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	Nil
<b>“E”</b>	Nil

+ See chapter 19 for defined terms.

For personal use only

<b>Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A</b>	
<p>"A" x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	<p>5,845,758</p>
<p><b>Subtract "E"</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	<p>Nil</p>
<p><b>Total</b> ["A" x 0.10] – "E"</p>	<p style="text-align: center;"><b>5,845,758</b></p> <p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

---

+ See chapter 19 for defined terms.

For personal use only



## Appendix A– Terms of Employee Options

1. **Employee Incentive Plan:**
  - (a) Each Tranche 1 Employee Option and Tranche 2 Employee Option (each an **Employee Option**) is granted pursuant to the Employee Incentive Plan of the Company.
  - (b) Terms defined in the rules of the Employee Incentive Plan (**Rules**) will, when used in these Terms of Employee Options, have the same meaning given to those terms under the Rules or the Notice (as the case may be) unless expressly stated otherwise in these Terms of Employee Options.
  - (c) Subdivision 83A-C of the *Income Tax Assessment Act 1997* (Cth) will apply (subject to the conditions in that Act) to the Employee Options.
2. **Entitlement:** Each Employee Option entitles the holder (**Option Holder**) to subscribe for 1 Share.
3. **No payment on grant:** The Option Holder is not required to pay any amount on the grant of an Employee Option.
4. **Exercise price:** The exercise price of each Employee Option (**Exercise Price**) is:
  - (a) in the case of a Tranche 1 Employee Option, \$0.79; and
  - (b) in the case of a Tranche 2 Employee Option, \$0.95.
5. **Expiry date:** Each Employee Option not exercised by 5.00pm (WST) on the following dates (each an **Expiry Date**) will automatically lapse and terminate:
  - (a) in the case of a Tranche 1 Employee Option, 31 August 2020; and
  - (b) in the case of a Tranche 2 Employee Option, 31 July 2020.
6. **Certificate or holding statement:** The Company must give the Option Holder a certificate or holding statement stating:
  - (a) the number of Employee Options granted to the Option Holder;
  - (b) the Exercise Price of the Employee Options; and
  - (c) the date of grant of the Employee Options.
7. **Restrictions on dealing and transfer:**
  - (a) An Option Holder must not sell, transfer, mortgage, pledge, charge, grant a security interest over or otherwise dispose of (**Dispose**) any Employee Options, or agree to do any of the same, without the prior consent of the Board, except where such Disposal occurs by force of law.
  - (b) The transfer of any Employee Option is subject to any restrictions on transfer under the Corporations Act or the Listing Rules.
8. **Quotation of Employee Options:** The Company will not apply for quotation of any Employee Options.
9. **New issues:** The Option Holder is not entitled to participate in any new issue to the Shareholders of securities in the Company unless they have exercised their Employee Options before the record date for determining entitlements to the new issue of securities and participate as a result of holding Shares. The Company must give the Option Holder notice of the proposed terms of the issue or offer in accordance with the Listing Rules.

For personal use only

10. **Bonus issues:** If the Company makes a bonus issue of Shares or other securities to Shareholders (except an issue in lieu of dividends or by way of dividend reinvestment) and a Share has not been issued in respect of the Employee Option before the record date for determining entitlements to the issue, then the number of underlying Shares over which the Employee Option is exercisable will be increased by the number of Shares which the Option Holder would have received if the Option Holder had exercised the Employee Option before the record date for determining entitlements to the issue.
11. **Pro rata issues:** If the Company makes a pro rata issue of Shares (except a bonus issue) to Shareholders (except an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment) and a Share has not been issued in respect of the Employee Option before the record date for determining entitlements to the issue, the Exercise Price of each Employee Option will be reduced in accordance with the Listing Rules.
12. **Reorganisation:**
- (a) If there is a reorganisation (including consolidation, sub-division, reduction or return) of the share capital of the Company, then the rights of the Option Holder (including the number of Employee Options to which the Option Holder is entitled to and the Exercise Price) will be changed to the extent necessary to comply with the Listing Rules applying to a reorganisation of capital at the time of the reorganisation.
  - (b) Any calculations or adjustments which are required to be made will be made by the Company's Board of Directors and will, in the absence of manifest error, be final and conclusive and binding on the Company and the Option Holder.
  - (c) The Company must, within a reasonable period, give to the Option Holder notice of any change to the Exercise Price of any Employee Options held by the Option Holder or the number of Shares which the Option Holder is entitled to subscribe for on exercise of an Employee Option.
13. **Exercise:**
- (a) Subject to 13(b), an Option Holder may:
    - (i) not exercise an Employee Option during the period (**Restriction Period**) commencing on the date that an Employee Option is granted and expiring on the later of:
      - A. the date that the last Vesting Condition (if any) is satisfied or waived by the Company; and
      - B. the date when the last Exercise Condition (if any) is satisfied or waived by the Company; and
    - (ii) only exercise an Employee Option after the expiry of the Restriction Period but prior to the Expiry Date.
  - (b) Notwithstanding paragraph 13(a), an Employee Option may be exercised:
    - (i) in the Board's absolute discretion, at any time after a Change of Control Event has occurred;
    - (ii) at any time after the announcement of a proposed capital reorganisation referred to in paragraph 12;
    - (iii) in the Board's absolute discretion, following the occurrence and announcement by the Company of an event that in the opinion of the Board is likely to lead to the Company being removed from the official list of ASX; or
    - (iv) in the Board's absolute discretion, within 12 months, if any of the following occurs in relation to a Participant, in relation to Employee Options held by or on behalf of that Participant:

- For personal use only
- A. the illness or incapacity of the Participant necessitating the permanent withdrawal of the Participant from the work force, as accepted to the satisfaction of the Board; or
  - B. any other circumstances which the Board considers should be treated as permanent disablement of the Participant for the purposes of the Employee Incentive Plan.
- (c) To exercise Employee Options, the Option Holder must give the Company or its securities registry, at the same time:
- (i) a written exercise notice (in the form approved by the board of the Company from time to time) specifying the number of Employee Options being exercised and Shares to be issued;
  - (ii) payment of the Exercise Price for the Employee Options the subject of the exercise notice, by way of bank cheque or by other means of payment, approved by the Company;
  - (iii) the Certificate, or documentary evidence satisfactory to the Board that the Certificate was lost or destroyed; and
  - (iv) where required by the Company in accordance with rule 19.2 of the Rules, payment in full of the amount of Withholding Tax Amount that the Company is required to remit as a result of the exercise of the Employee Option.
- (d) Where a payment is received by the Company under paragraph 13(c)(iv), those moneys will be held on behalf of the Participant, and remitted to the appropriate taxing authority by the Company on behalf of the Participant as soon as reasonably practicable.
- (e) The Option Holder may only exercise Employee Options in multiples of 500 Employee Options unless the Option Holder holds less than 500 Employee Options.
- (f) A notice of exercise in relation to any Employee Options only becomes effective when the Company has received the full amount of the Exercise Price for the number of Employee Options specified in the notice, in cleared funds.
- (g) Employee Options will be deemed to have been exercised on the date the exercise notice is lodged with the Board.
14. **Re-issue of certificate or holding statement:** If the Option Holder exercises less than the total number of Employee Options registered in the Option Holder's name:
- (a) the Option Holder must surrender their Employee Option certificate (if any); and
  - (b) the Company must cancel the Employee Option certificate (if any) and issue the Option Holder a new Employee Option certificate or holding statement stating the remaining number of Employee Options held by the Option Holder.
15. **Issue of Shares:** Within 10 days after receiving an application for exercise of Employee Options and payment by the Option Holder of the Exercise Price, the Company must issue the Option Holder the number of Shares specified in the application.
16. **Equal ranking:** Subject to the Company's Constitution, all Shares issued on the exercise of Employee Options will rank in all respects (including rights relating to dividends) equally with the existing ordinary Shares of the Company at the date of issue.
17. **Quotation of Shares:** The Company will apply to ASX for official quotation of the Shares issued on exercise of Employee Options.
18. **Bad Leaver:** Each Employee Option that has not been exercised and not expired will automatically lapse and be forfeited if the Participant to which the Employee Option relates

ceases employment or engagement as a Contractor with the Group Companies as a Bad Leaver.

19. **Good Leaver:** An Employee Option will not lapse and be forfeited if the Participant to which the Employee Option relates ceases employment or engagement as a Contractor with any Group Companies as a Good Leaver.
20. **Governing law:** These terms and the rights and obligations of the Option Holder are governed by the laws of Western Australia. The Option Holder irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of Western Australia.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: AURORA LABS LIMITED</b>
<b>ABN 44 601 164 505</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David James Budge
<b>Date of last notice</b>	14 July 2017

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: David James Budge ATF <Budge Family Trust> Relevant interest: Trustee & beneficiary
<b>Date of change</b>	29 November 2017
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. 23,946,785 Ordinary Shares</li> <li>2. 725,000 Options (Ex \$0.20/Exp 31/12/2018)</li> <li>3. 4,973,563 Class B Performance Shares</li> <li>4. 5,341,975 Class C Performance Shares</li> <li>5. 115,000 Options (Ex \$2.23/ Exp 30/11/2019)</li> <li>6. 165,000 Options (Ex \$3.00/ Exp 31/03/2020)</li> </ol>
<b>Class</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares</li> <li>2. Unquoted Options (Ex\$0.20/ Expiry 31/12/2018)</li> <li>3. Class B Performance Shares</li> <li>4. Class C Performance Shares</li> <li>5. Unquoted Options (Ex \$2.23/Expiry 30/11/2019)</li> <li>6. Unquoted Options (Ex \$3.00/Expiry 31/3/2020)</li> <li>7. Unquoted Options (Ex \$0.79/Expiry 31/8/2020)</li> </ol>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	7. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020)
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.1861 per Option (\$2,792)* *Estimated valuation based on Black-Scholes Model - refer to ASX Announcement 27 October 2017 Page 13 of Notice of Annual General Meeting.
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 23,946,785 Ordinary Shares</li> <li>2. 725,000 Options (Ex \$0.20/Exp 31/12/2018)</li> <li>3. 4,973,563 Class B Performance Shares</li> <li>4. 5,341,975 Class C Performance Shares</li> <li>5. 115,000 Options (Ex \$2.23/ Exp 30/11/2019)</li> <li>6. 165,000 Options (Ex \$3.00/ Exp 31/03/2020)</li> <li>7. 15,000 Options (Ex \$0.079/ Exp 31/08/2020)</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	7. Grant of Options pursuant to Aurora Labs Limited Employee Incentive Plan as approved by shareholders at Annual General Meeting held on 29 November 2017.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity: AURORA LABS LIMITED</b>
<b>ABN: 44 601 164 505</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Nathan Henry
<b>Date of last notice</b>	14 July 2017

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect & Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Registered Holder: Buttes Pty Ltd <Toklat A/C> Relevant interest: Director
<b>Date of change</b>	29 November 2017
<b>No. of securities held prior to change</b>	<p><u>Direct</u></p> <ol style="list-style-type: none"> <li>1. 832,151 Ordinary Shares</li> <li>2. 1,693,334 Unquoted Options (Ex \$0.20/ Expiry 31/12/2018)</li> <li>3. 172,832 Class B Performance Shares</li> <li>4. 185,634 Class C Performance Shares</li> </ol> <p><u>Indirect</u></p> <ol style="list-style-type: none"> <li>1. 150,000 Ordinary Shares</li> <li>5. 140,000 Unquoted Options (Ex \$2.23/Expiry 30/11/2019)</li> <li>6. 125,000 Unquoted Options (Ex \$3.00/Expiry 31/3/2020)</li> </ol>

+ See chapter 19 for defined terms.

For personal use only



**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares</li> <li>2. Unquoted Options (Ex\$0.20/ Expiry 31/12/2018)</li> <li>3. Class B Performance Shares</li> <li>4. Class C Performance Shares</li> <li>5. Unquoted Options (Ex \$2.23/Expiry 30/11/2019)</li> <li>6. Unquoted Options (Ex \$3.00/Expiry 31/3/2020)</li> <li>7. Unquoted Options (Ex \$0.79/Expiry 31/8/2020)</li> </ol>
<b>Number acquired</b>	<u>Indirect</u> <ol style="list-style-type: none"> <li>7. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020)</li> </ol>
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.1861 per Option (\$2,792)* *Estimated valuation based on Black-Scholes Model - refer to ASX Announcement 27 October 2017 Page 13 of Notice of Annual General Meeting.
<b>No. of securities held after change</b>	<u>Direct</u> <ol style="list-style-type: none"> <li>1. 832,151 Ordinary Shares</li> <li>2. 1,693,334 Options (Ex \$0.20/Exp 31/12/2018)</li> <li>3. 172,832 Class B Performance Shares</li> <li>4. 185,634 Class C Performance Shares</li> </ol> <u>Indirect</u> <ol style="list-style-type: none"> <li>1. 150,000 Ordinary Shares</li> <li>5. 140,000 Options (Ex \$2.23/ Exp 30/11/2019)</li> <li>6. 125,000 Options (Ex \$3.00/Exp 31/03/2020)</li> <li>7. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020)</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> <li>7. Grant of Options pursuant to Aurora Labs Limited Employee Incentive Plan as approved by shareholders at Annual General Meeting held on 29 November 2017.</li> </ol>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> AURORA LABS LIMITED
<b>ABN</b> 44 601 164 505

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mathew Whyte
<b>Date of last notice</b>	26 July 2017

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Registered Holder: M&S Whyte <Family A/c> Relevant Interest: Mr Whyte is a trustee and beneficiary
<b>Date of change</b>	29 November 2017
<b>No. of securities held prior to change</b>	1. 50,000 Unquoted Options (Ex \$3.00/Expiry 31/3/2020)
<b>Class</b>	1. Unquoted Options (Ex \$3.00/Expiry 31/3/2020) 2. Unquoted Options (Ex \$0.79/Expiry 31/8/2020) 3. Unquoted Options (Ex \$0.95/ Expiry 31/7/2020)

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	2. 15,000 Unquoted Options (Ex \$0.79/Expiry 31/08/2020) 3. 100,000 Unquoted Options (Ex \$0.95/ Expiry 31/07/2020)
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	2. \$0.1861 per Option (\$2,792)* 3. \$0.1686 per Option (\$16,860)*  *Estimated valuation based on Black-Scholes Model - refer to ASX Announcement 27 October 2017 Page 13 of Notice of Annual General Meeting.
<b>No. of securities held after change</b>	1. 50,000 Options (Ex \$3.00/ Exp 31/03/2020) 2. 15,000 Options (Ex \$0.079/ Exp 31/08/2020) 3. 100,000 Unquoted Options (Ex \$0.95/ Expiry 31/07/2020)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	2. & 3. Grant of Options pursuant to Aurora Labs Limited Employee Incentive Plan as approved by shareholders at Annual General Meeting held on 29 November 2017.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only